Android app on Google Play

Morning Movers 05/29: (BTFG) (LCRY) (IBI) (CNTF) Higher; (VRTX) Lower

May 29, 2012 10:53 AM EDT Send to a Friend
Get Alerts BTFG Hot Sheet
Trade BTFG Now!
Join SI Premium – FREE
BancTrust Financial Group, Inc. (Nasdaq: BTFG) 56.8% HIGHER; Trustmark Corporation (Nasdaq: TRMK) and BancTrust have signed a definitive agreement pursuant to which BancTrust will merge into Trustmark. BancTrust has 49 offices throughout Alabama and the Florida Panhandle with $1.3 billion in loans and $1.8 billion in deposits as of March 31, 2012.

LeCroy Corporation (Nasdaq: LCRY) 56.2% HIGHER; Teledyne Technologies Incorporated (NYSE: TDY) and LeCroy jointly announced today that they have entered into a definitive agreement that provides for the merger of LeCroy Corporation with a wholly-owned subsidiary of Teledyne. Pursuant to the transaction, Teledyne will acquire all of the outstanding common shares of LeCroy for $14.30 per share payable in cash.

Interline Brands, Inc. (NYSE: IBI) 39.9% HIGHER; has entered into a definitive agreement to be acquired by affiliates of GS Capital Partners LP and P2 Capital Partners, LLC for $25.50 per share in cash.

China Techfaith Wireless Communication Technologies (Nasdaq: CNTF) 38.7% HIGHER; breaking out after the stock held above the $1 level on Friday. The price jumped over $1.25 just following this morning's opening bell.

North American Energy Partners Inc. (NYSE: NOA) 28.3% HIGHER; today announced that Martin Ferron will join the Company as President and Chief Executive Officer and a Director of the Board effective at the close of business on June 7, 2012.

Genetic Technologies (Nasdaq: GENE) 20.9% HIGHER; continuing a volatile run this week. After jumped 65 percent on Tuesday, falling 11 percent on Wednesday, surging another 63 percent on Thursday, and falling 16 percent to close last week's trading, shares are back over $5 once gain.

Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) 16.7% LOWER; under heavy pressure early Tuesday after correcting data about lung function from a Phase 2 trial of VX-809 and KALYDECO in cystic fibrosis patients sharply lower. Click here to see the full report.




You May Also Be Interested In


Related Categories

Special Reports

Related Entities

Morning Movers, P2 Capital

Add Your Comment